Efficacy and safety of intralymphatic immunotherapy in allergic rhinitis: A systematic review and meta-analysis

Nor Rahimah Aini¹ | Norhayati Mohd Noor² | Mohd Khairi Md Daud¹ | Sarah K. Wise³ | Baharudin Abdullah¹

¹Department of Otorhinolaryngology-Head and Neck Surgery, School of Medical Sciences, Universiti Sains Malaysia Health Campus, Kelantan, Malaysia
²Department of Family Medicine, School of Medical Sciences, Universiti Sains Malaysia, Kelantan, Malaysia
³Department of Otolaryngology-Head & Neck Surgery, Emory University School of Medicine, Atlanta, Georgia, USA

Correspondence
Baharudin Abdullah, Department of Otorhinolaryngology-Head and Neck Surgery, School of Medical Sciences, Universiti Sains Malaysia Health Campus, 16150 Kubang Kerian, Kelantan, Malaysia.
Email: profbaha@gmail.com

Abstract
Background: Intralymphatic immunotherapy (ILIT) is a potential treatment option for allergic rhinitis (AR). We aimed to determine the efficacy (primary outcomes) and safety (secondary outcomes) of ILIT in treating patients with AR.

Methods: An electronic literature search was performed using MEDLINE and Cochrane Central Register of Controlled Trials CENTRAL (from their inception to December 2020). A random-effects model was used to estimate the pooled prevalence with 95% confidence intervals. This study is registered with PROSPERO (CRD42019126271).

Results: We retrieved a total of 285 articles, of which 11 satisfied our inclusion criteria. There were 452 participants with age ranged from 15 to 58 years old. Intralymphatic immunotherapy was given in three doses with intervals of four weeks between doses in 10 trials. One trial gave three and six doses with an interval of two weeks. Both primary and secondary outcomes showed no difference between ILIT and placebo for all trials. There was no difference in the combined symptoms and medication score (SMD -0.51, 95% CI −1.31 to 0.28), symptoms score (SMD −0.27, 95% CI −0.91 to 0.38), medication score (SMD −6.56, 95% CI −21.48 to 8.37), rescue medication (RR 12.32, 95% CI 0.72–211.79) and the overall improvement score (MD -0.07, 95% CI −2.28 to 2.14) between ILIT and placebo. No major adverse events noted.

Conclusions: Intralymphatic immunotherapy possibly has a role in the treatment of AR patients. This review found it is safe but not effective, which could be contributed by the high variation amongst the trials. Future trials should involve larger numbers of participants and report standardized administration of ILIT and outcome measures.

Keywords
allergen-specific immunotherapy, allergic rhinitis, efficacy, intralymphatic immunotherapy, safety
1 | BACKGROUND

The prevalence of self-reported allergic rhinitis (AR) has been estimated to be approximately 25% in children and more than 40% in adults. Allergic rhinitis is frequently associated with asthma which is found in 15%–38% of AR patients while nasal symptoms present in 6%–85% of patients with asthma. The management of AR involves patient education, allergen (and pollutant) avoidance, pharmacotherapy, and allergen-specific immunotherapy (AIT) when appropriate. Pharmacologic options for the treatment of AR include intranasal corticosteroids, oral and topical antihistamines, decongestants, intranasal cromolyn, intranasal anticholinergics and leukotriene receptor antagonists, amongst others. A recent advance has been the combination of an antihistamine and a corticosteroid in the same nasal spray.

Allergen-specific immunotherapy should be considered for patients with moderate or severe persistent AR that is not responsive to pharmacological treatments. The most widely employed form of AIT involves the administration, subcutaneously or sublingually, of increasing doses of the causative allergen to induce clinical and immunologic tolerance. However, the conventional subcutaneous immunotherapy (SCIT) requires 30 to 80 allergen injections over three to five years and maybe associated with allergic side effects. Sublingual immunotherapy (SLIT) is more patient-friendly, but treatment duration could not be shortened. Intralymphatic immunotherapy (ILIT) is a potential treatment option to overcome these limitations.

Intralymphatic immunotherapy is a form of AIT where the allergen is directly delivered to B- and T-cells within the lymph nodes. This procedure is reported to induce a stronger cytotoxic T-cell response and higher immunogenicity than other routes, even with the delivery of smaller amounts of allergen as typically employed in ILIT. Allergenic extract is usually injected into inguinal lymph nodes using ultrasound guidance. Therapy is complete after only three injections. When given four weeks apart, ILIT is reported to be safe and effective for up to three years. In patients with allergic rhinitis that require immunotherapy treatment, ILIT might be an option to treat their symptoms. This meta-analysis aimed to evaluate the efficacy and safety of ILIT in the treatment of AR.

2 | METHODS

A systematic review and meta-analysis were undertaken in accordance with the preferred reporting items for systematic reviews and

| Table 1 | Search strategy |
|----------------|------------------|
| **Databases** | **Search strategy** |
| PubMed | (Allergic rhinitis [Title/Abstract]) OR (rhinoconjunctivitis [Title/Abstract]) AND (intralymphatic immunotherapy [Title/Abstract]) OR (intralymphatic allergen [Title/Abstract]) AND (subcutaneous immunotherapy [Title/Abstract]) AND (randomized controlled trial [Filter]) OR (sublingual immunotherapy [Title/Abstract]) |
| Cochrane | Allergic rhinitis in title abstract keyword AND intralymphatic immunotherapy in title abstract keyword |
symptoms improvement. The secondary outcomes were adverse event reports (i.e., anaphylaxis or other systemic reaction, reactivation of herpes zoster), specific IgE antibody level, allergen sensitivity measures via wheal change after skin prick test and quality of life measures. The risk of bias assessment was based on random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessors, completeness of outcome data, the selectivity of outcome reporting and other bias. Any disagreements were resolved by discussion.

The meta-analyses were done using Review Manager 5.3.5 software.\textsuperscript{17} The statistical analyses were performed using the random-effects model and the results expressed as risk ratio (RR) for dichotomous outcomes and mean difference (MD) for continuous outcomes with 95\% confidence intervals (CI). The included trials were checked for unit of analysis errors. If any cluster-RCTs were encountered, the results from trials were adjusted to show a unit of analysis errors based on mean cluster size and intracluster correlation coefficient.\textsuperscript{15} If studies have non-extractable or missing data, analyses of the available data were performed. The presence of heterogeneity was assessed in two steps. First, obvious heterogeneity at face value was assessed by comparing populations, settings, interventions and outcomes. Second, statistical heterogeneity was assessed through the $I^2$ statistic.\textsuperscript{16} The heterogeneity was interpreted as outlined: 0\% to 40\% might not be important; 30\% to 60\% may represent moderate heterogeneity; 50\% to 90\% may represent substantial heterogeneity, and 75\% to 100\% would be considerable heterogeneity.\textsuperscript{16}

3 | RESULTS

A total of 285 records were retrieved and screened from the search of electronic databases (Figure 1). Fifteen full-text articles were assessed for eligibility and four records were excluded. Three trials\textsuperscript{19–21} excluded from the review due to no control group while one trial\textsuperscript{22} did not meet the inclusion criteria. 11 articles\textsuperscript{10,13,18,23–28} were included in the review. The characteristics of the included trials are shown in Table 2.

3.1 | Participants

A total of 452 participants were enrolled in the included trials. Nine trials\textsuperscript{10,13,18,23,24,26–28} involved patients 18 years old and older. Two trials\textsuperscript{10,23} by the same investigators have duplicates participants; a succeeding trial\textsuperscript{25} included 15 participants from an initial study (first cohort)\textsuperscript{10}. Thus, the former trial analysis was based on the second cohort of patients with 21 participants. Two trials\textsuperscript{18,25} reported a younger age group from 15 years old. 10 trials\textsuperscript{10,11,13,23,28} involving 369 participants mentioned the gender of the participants with a male to female ratio of 1.5:1. Eight trials\textsuperscript{10,12,23,24,26–28} reported exclusion of participants due to pregnancy or nursing, planning for pregnancy, autoimmune disease, perennial asthma or any other cardiopulmonary disease. In contrast, one trial\textsuperscript{25} includes mild young adult asthma as an inclusion criterion.

3.2 | Intervention

Participants in the trials were randomized into intervention and control groups. Seven trials\textsuperscript{11,13,18,26–28} used a single allergen as the ILIT intervention. Four trials\textsuperscript{10,23–25} used two different allergens, but only one trial\textsuperscript{24} assessed the result of two different allergens individually. Grass pollen extract was administered in eight trials,\textsuperscript{10,11,13,18,23–26} birch pollen extract in four trials,\textsuperscript{10,23–25} cedar pollen extract was administrated in two trials\textsuperscript{27,28} and one trial\textsuperscript{12} used cat dander allergen extract (MAT-Fel d 1).

The allergen was administered via superficial inguinal lymph nodes using ultrasound guidance in all 11 trials.\textsuperscript{10,13,18,23–28} In 10 trials,\textsuperscript{10,12,18,23–28} ILIT was given in three doses with intervals of four weeks between doses. One trial\textsuperscript{12} administered three and six doses with an interval of two weeks. The same dose of allergen was administered in nine trials. Eight trials\textsuperscript{10,11,13,23–27} administered 0.1 ml of 1000 SQ-U each while one trial\textsuperscript{28} used 0.1 ml of 20 Japanese Allergy Units (JAU). In contrast, two other trials\textsuperscript{12,16} administered a tapering dose of 1, 3, and 10 μg for cat dander allergen extract and 0.1, 0.2, and 0.5 ml of 20,000 PNU/ml for grass pollen extract. Three trials\textsuperscript{11,26,28} assessed the long term outcome up to three years since the initiation of treatment. Placebo was used as a control group in 10 trials\textsuperscript{10,12,13,18,23–28} while two trials (including a pilot study by Hylander et al.)\textsuperscript{10,11} used a SCIT control group.

3.3 | Outcomes

Three trials reported the symptoms score.\textsuperscript{13,25,27} Symptoms score was scored on a 0–3 points scale corresponding to no symptoms, mild, moderate or severe symptoms for two trials\textsuperscript{13,27} while one trial\textsuperscript{25} scored on 0–4 points scale based on the frequency of symptoms: daily (4 points); every second day (3 points); 1–3 days per week (2 points); occasionally (1 point); never (0 points). Medication score was reported in three trials.\textsuperscript{13,25,27} The medication score was calculated based on the use of daily medications (consisting of an oral antihistamine, antihistamine eye drop, nasal corticosteroid and oral corticosteroid). The maximum daily points were 20 in one trial\textsuperscript{27} and 24 in another trial\textsuperscript{13}. Five trials\textsuperscript{13,18,26–28} reported the combined symptoms medication score. The combined symptoms medication score is the sum of the daily symptoms score and medication score. Eight trials\textsuperscript{10,11,13,23–25,28} reported the overall improvement score. The overall improvement score was reported in a visual analog scale ranging from zero (unchanged symptoms or no improvement) to 10 (total symptoms relief or complete recovery) when asked to compare allergic symptoms during recent pollen season versus the previous experienced season before the treatment started. Three trials\textsuperscript{10,23,24} reported the rescue medication in
which they reported the number of patients with reduced rescue medication. An oral antihistamine, intranasal corticosteroid nasal spray and antihistamine eye drop were used as rescue medication in all included trials while β₂-agonist and steroid inhaler were additionally given to the asthmatic patients. We analyzed the reduction of rescue medication based on the reduction of oral antihistamine and inhaled β₂-agonist.

All included trials reported secondary outcomes. Adverse events of the treatment were reported based on the number of patients who developed symptoms after injection was given, and the severity of side effects as described. One trial reported the occurrence of adverse events based on the number of injections. The time points of measurement vary between trials: first-hour post-injection; 24 h post-injection, 1 week post-injection; 88 days post-injection; 4 months post-injection and two trials did not mention the exact time of measurement. The adverse events include local swelling at site of injection, abdominal symptoms, nonspecific symptoms such as headache, fatigue and muscle soreness and eye and nasal itchiness. Two trials reported the pre and post-treatment serum IgE level were included for the analysis. Four trials reported the quality of life after treatment. Quality of life was measured with Juniper Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) for two

![Study flow diagram]

**FIGURE 1** Study flow diagram
| First author, year | Study design | No of patients/ No of trial sites | Diagnosis | Intervention | Control | Injection interval |
|--------------------|--------------|-----------------------------------|-----------|-------------|---------|-------------------|
| Senti 2008         | RCT          | 165/1                             | Patients with seasonal rhinoconjunctivitis | Grass pollen | Grass pollen vaccine via subcutaneous injection | 4 weeks |
| Senti 2011         | RCT          | 20/1                              | Patients with cat dander allergy | MAT- Fel d 1 (cat dander modified recombinant allergen) | Placebo via intralymphatic injection | 28 ± 3 days |
| Hylander 2013      | RCT          | 15/1                              | Patients with birch- pollen or grass-pollen rhinoconjunctivitis | Birch or grass pollen | Placebo via intralymphatic injection | 4 weeks |
| Hylander 2013      | Case control | 13/1                              | Patients with birch- pollen or grass- pollen rhinoconjunctivitis | Birch or grass pollen | Birch-pollen vaccine via subcutaneous injection | 4 weeks |
| Witten 2013        | RCT          | 45/1                              | Patients with grass pollen rhinoconjunctivitis | Grass pollen | Placebo via intralymphatic injection | 14 days |
| Hylander 2016      | RCT          | 36/1                              | Patients with birch or grass pollen rhinoconjunctivitis | Birch or grass pollen | Placebo via intralymphatic injection | 3 to 4 weeks |
| Patterson 2016     | RCT          | 15/1                              | Patients with allergy to grass pollen | Grass pollen | Placebo via intralymphatic injection | 4 weeks |
| Hellkvist 2018     | RCT          | 60/2                              | Patients with both birch and grass rhinoconjunctivitis | Grass and birch pollen | Placebo via intralymphatic injection | 4 weeks |
| Konradsen 2019     | RCT          | 30/1                              | Patients with birch and/or timothy grass pollen rhinoconjunctivitis | Birch or grass pollen | Placebo via intralymphatic injection | 4 weeks |
| Thompson 2020      | RCT          | 21/3                              | Patients with mountain cedar allergy | Mountain cedar pollen | Placebo via intralymphatic injection | 4 weeks |
| Terada 2020        | RCT          | 18/1                              | Patients with severe Japanese cedar pollen allergic rhinitis | Japanese cedar pollen | Placebo via intralymphatic injection | 4 weeks |
| Skaarup 2020       | RCT          | 36/1                              | Patients with grass pollen rhinoconjunctivitis | Grass pollen | Placebo via intralymphatic injection (1 or 3 placebo) | 4 weeks |

Abbreviation: RCT, randomized controlled trial.
Risk of bias summary for individual study

![Bias Summary Table]

3.4 | Risk of bias in included studies

The assessment of the risk of bias for individual trials is presented in Figure 2. Seven trials\textsuperscript{10,12,13,18,23-27} described the method of randomization used. Four trials\textsuperscript{10,23-25} randomized the participants using simple randomization with a ratio of one placebo to one patient who received the intervention. Three trials\textsuperscript{12,25,27} randomized the participants according to a pre-printed allocation list generated by a private analytical company (IKFE GmbH, Germany),\textsuperscript{12} randomizer.org\textsuperscript{26} and REDCap Cloud EDC system\textsuperscript{27} using block randomization. The randomization method was not reported in five trials\textsuperscript{10,11,18,23,28}, thus, we considered random sequence generation as an unclear risk bias. Allocation concealment was not clear in four trials\textsuperscript{11,18,26,28}.

3.5 | Blinding

Placebo was used as the control group in 10 trials,\textsuperscript{10,12,13,18,23-28} while SCIT was used as the control group by Senti et al.\textsuperscript{11} and in a pilot study by Hylander et al.\textsuperscript{10} Both patients and investigators were blinded in eight trials\textsuperscript{10,12,13,23-27} The control group in one trial\textsuperscript{11} received subcutaneous injection as immunotherapy; thus, both patient and investigator were not blinded throughout the study. Two trials\textsuperscript{18,28} did not describe blinding. One trial\textsuperscript{24} had detection bias due to an error during the outcome assessment.

3.6 | Incomplete outcome data

All trials\textsuperscript{10-13,18,23-28} were carried out as an intention-to-treat analysis. The non-response rate for seven trials\textsuperscript{11,13,23,26,28} were balanced (less than 20%), and the reasons were similar between the groups. Two trials\textsuperscript{23,24} recorded individual’s withdrawal from the study after the first injection due to side-effects at local injection site; however, they were included in the safety analysis.

3.7 | Selective reporting

All 11 trials\textsuperscript{10-13,18,23-28} reported the outcomes as specified in their method section. All trials were prospectively registered in the WHO ICTRP and www.clinicaltrials.gov except for two trials.\textsuperscript{10,28} The outcomes listed in the registered protocol were those reported.

3.8 | Primary outcomes

There are two comparisons for this review (i) ILIT versus placebo and (ii) ILIT versus SCIT. There are 10 trials\textsuperscript{10-13,18,23-25,27,28} involved in the former, while two trials,\textsuperscript{10,11} including a pilot study in the latter. The trials for comparing ILIT versus SCIT could not be analyzed as each trial assessed different outcomes. Nine out of 11 trials\textsuperscript{10,11,13,18,23-27} contributed to the primary outcomes. Primary outcomes include combined symptoms medication score, medication score, symptoms score, medication reduction and overall improvement score. All trials contributed to the secondary outcomes. Four trials\textsuperscript{13,18,26,27} reported no difference in the combined symptoms and medication score following treatment between ILIT and placebo (SMD −0.51, 95% CI −1.31 to 0.28; \(p = 0.210\); \(I^2 = 71\%\); 4 trials, 99 participants; low certainty
Comparison between ILIT and placebo for combined symptoms medication score

| Study or Subgroup | ILIT Mean | SD | Total | Placebo Mean | SD | Total | Weight | Std. Mean Difference IV, Random, 95% CI | Std. Mean Difference IV, Random, 95% CI |
|-------------------|----------|----|-------|--------------|----|-------|--------|---------------------------------------|---------------------------------------|
| Patterson 2016    | 8        | 6.3| 14    | 7            | 16| 23.2  | 8      | -0.76 [-1.82, 0.30]                   |                                       |
| Skaarup 2020      | 0.31     | 0.28| 24    | 0.62         | 0.27| 12    | 27.1   | -1.10 [-1.84, -0.35]                 |                                       |
| Thompson 2010     | 10.5     | 2.7| 11    | 13.3         | 3.9| 10    | 24.5   | -0.81 [-1.71, 0.09]                  |                                       |
| Witten 2013       | 0.19     | 0.03| 14    | 0.17         | 0.04| 13    | 26.7   | 0.55 [-0.22, 1.32]                   |                                       |
| Total (95% CI)    | 56       |     |       | 43           |     |       | 100.0% | -0.51 [-1.31, 0.28]                 |                                       |

Heterogeneity: Tau² = 0.46; Chi² = 10.28; df = 3 (P = 0.02); I² = 71%
Test for overall effect: Z = 1.27 (P = 0.21)

Comparison between ILIT and placebo for symptoms score

| Study or Subgroup | ILIT Mean | SD | Total | Placebo Mean | SD | Total | Weight | Std. Mean Difference IV, Random, 95% CI | Std. Mean Difference IV, Random, 95% CI |
|-------------------|----------|----|-------|--------------|----|-------|--------|---------------------------------------|---------------------------------------|
| Konradsen 2020    | -46.7    | 48.87| 11    | -18.8        | 16.8| 9     | 30.2%  | -0.70 [-1.61, 0.21]                   |                                       |
| Thompson 2020     | 4.7      | 2.7 | 11    | 6.3          | 3   | 10    | 31.8%  | -0.54 [-1.42, 0.34]                  |                                       |
| Witten 2013       | 0.15     | 0.02| 14    | 0.14         | 0.04| 14    | 38.0%  | 0.31 [-0.44, 1.05]                   |                                       |
| Total (95% CI)    | 36       |     |       | 33           |     |       | 100.0% | -0.27 [-0.91, 0.38]                 |                                       |

Heterogeneity: Tau² = 0.14; Chi² = 3.49; df = 2 (P = 0.17); I² = 43%
Test for overall effect: Z = 0.82 (P = 0.42)

Comparison between ILIT and placebo for medication score

| Study or Subgroup | ILIT Mean | SD | Total | Placebo Mean | SD | Total | Weight | Std. Mean Difference IV, Random, 95% CI | Std. Mean Difference IV, Random, 95% CI |
|-------------------|----------|----|-------|--------------|----|-------|--------|---------------------------------------|---------------------------------------|
| Thompson 2020     | 5.4      | 2.8 | 11    | 67           | 5.2| 10    | 48.7%  | -14.37 [-19.27, -9.47]               |                                       |
| Witten 2013       | 0.23     | 0.04| 14    | 0.19         | 0.05| 13    | 51.3%  | 0.86 [0.07, 1.66]                    |                                       |
| Total (95% CI)    | 25       |     |       | 23           |     |       | 100.0% | -6.56 [-21.48, 8.37]                 |                                       |

Heterogeneity: Tau² = 112.78; Chi² = 36.20; df = 1 (P < 0.00001); I² = 97%
Test for overall effect: Z = 0.86 (P = 0.39)

Comparison between ILIT and placebo for overall improvement score

| Study or Subgroup | ILIT Mean | SD | Total | Placebo Mean | SD | Total | Weight | Mean Difference IV, Random, 95% CI | Mean Difference IV, Random, 95% CI |
|-------------------|----------|----|-------|--------------|----|-------|--------|-----------------------------------|-----------------------------------|
| Helvikst 2018     | 5        | 3.6 | 25    | 3.6          | 3.1| 27    | 37.9%  | 1.40 [-0.43, 3.23]                |                                   |
| Konradsen 2020    | 4.55     | 7.88| 14    | 4.25         | 6.68| 12    | 12.0%  | 0.30 [-5.30, 5.90]                |                                   |
| Witten 2013       | 0.69     | 0.68| 14    | 1.96         | 0.49| 14    | 50.2%  | -1.27 [-1.71, -0.83]              |                                   |
| Total (95% CI)    | 53       |     |       | 53           |     |       | 100.0% | -0.07 [-2.28, 2.14]               |                                   |

Heterogeneity: Tau² = 2.49; Chi² = 7.96; df = 2 (P = 0.02); I² = 75%
Test for overall effect: Z = 0.06 (P = 0.95)

FIGURE 3 Primary outcomes of intralymphatic immunotherapy versus placebo

evidence) (Figure 3, Table 3). Three trials showed no difference in symptoms score following treatment between ILIT and placebo (SMD –0.27, 95% CI –0.91 to 0.38; p = 0.420; I² = 43%; 3 trials, 69 participants; moderate certainty evidence) (Figure 3, Table 3). Two trials described no difference in medication score following treatment between ILIT and placebo (SMD –6.56, 95% CI –21.48 to 8.37; p = 0.390; I² = 97%; 2 trials, 48 participants; very low certainty evidence) (Figure 3, Table 3). One trial reported that reduction of rescue medication was higher in ILIT compared to placebo (RR 12.32, 95% CI 0.72 to 211.79; p = 0.080; 1 trial, 51 participants). Three trials reported no difference in the overall improvement score between ILIT and placebo (MD –0.07, 95% CI –2.28 to 2.14; p = 0.950; I² = 75%; 3 trials, 106 participants; low certainty evidence) (Figure 3, Table 3).

For ILIT versus SCIT group, one trial showed no difference in symptoms improvement during the next pollen season after the treatment (MD –0.60, 95% CI –1.74 to 0.54; p = 0.300; 1 trial; 13 participants). One trial comparing ILIT and SCIT, reported the reduction of rescue medication was higher in SCIT group compared to ILIT (RR 0.64, 95% CI 0.45 to 0.93; p = 0.020; 1 trial, 107 participants).
### TABLE 3 Summary of findings for intralymphatic immunotherapy versus placebo in treating allergic rhinitis

| Outcomes                                      | No of participants (studies) | Certainty of the evidence (GRADE) | Relative effect (95% CI) | Risk with placebo | Risk difference with allergen via ILIT |
|-----------------------------------------------|-----------------------------|-----------------------------------|--------------------------|--------------------|--------------------------------------|
| Symptom score                                 | 69 (3 RCTs)                 | ⬤⬤⬤⬤ MODERATE<sup>b</sup>         | -                        | The mean symptom score was 0 | SMD 0.27 lower (0.91 lower to 0.38 higher) |
| Local swelling                                | 228 (8 RCTs)                | ⬤⬤⬤⬤ LOW<sup>c</sup>             | RR 4.51 (0.81 to 25.06)  | Study population 139 per 1000 | 487 more per 1000 (26 fewer to 1000 more) |
| Specific Ig- E levels                         | 85 (2 RCTs)                 | ⬤⬤⬤⬤ LOW<sup>d</sup>             | -                        | The mean specific Ig- E levels was 0 | MD 5.63 higher (0.71 higher to 10.55 higher) |
| Quality of life                                | 88 (3 RCTs)                 | ⬤⬤⬤⬤ LOW<sup>e</sup>             | -                        | The mean quality of life was 0 | SMD 0.1 lower (0.86 lower to 0.67 higher) |
| Combined symptoms medication score            | 99 (4 RCTs)                 | ⬤⬤⬤⬤ LOW<sup>f</sup>             | -                        | The mean combined symptoms medication score was 0 | SMD 0.51 lower (1.31 lower to 0.28 higher) |
| Medication score                              | 48 (2 RCTs)                 | ⬤⬤⬤⬤ VERY LOW<sup>g</sup>        | -                        | The mean medication score was 0 | SMD 6.56 lower (21.48 lower to 8.37 higher) |
| Overall improvement score                     | 106 (3 RCTs)                | ⬤⬤⬤⬤ LOW<sup>f</sup>             | -                        | The mean overall improvement score was 0 | MD 0.07 lower (2.28 lower to 2.14 higher) |

Abbreviations: CI, Confidence interval; RR, Risk ratio; RCTs: randomized controlled trials; ILIT, Intralymphatic immunotherapy.

<sup>a</sup> *The risk in the intervention group* (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

<sup>b</sup> Small number of participants (<400).

<sup>c</sup> Substantial heterogeneity.

<sup>d</sup> Very small number participants (<100).

<sup>e</sup> Moderate heterogeneity with wide confidence interval.

---

### 3.9 Secondary outcomes

Intralymphatic immunotherapy showed no difference for local swelling at the site of injection in eight trials<sup>10,12,13,23-27</sup> compared to placebo (RR 4.51, 95% CI 0.81 to 25.06; p = 0.090; I² = 88%; 8 trials, 228 participants; low certainty evidence) (Figure 4, Table 3). Likewise, no difference was documented for other adverse events (local and systemic adverse effects) between ILIT and placebo: abdominal symptoms<sup>12,23,24</sup> (RR 1.28, 95% CI 0.24 to 6.91; p = 0.780; I² = 0%; 3 trials, 101 participants; moderate certainty evidence) (Figure 4), non-specific symptoms such as fatigue, headache and muscle soreness<sup>12,13,24,26</sup> (RR 1.19, 95% CI 0.37 to 3.79; p = 0.770; I² = 11%; 4 trials, 145 participants; moderate certainty evidence) (Figure 4) and eye and nasal symptoms<sup>10,12,13,23,24,26,28</sup> (RR 1.00, 95% CI 0.38 to 2.59; p = 1.000; I² = 35%; 7 trials, 235 participants; low certainty evidence) (Figure 4). In the ILIT versus SCIT group, one trial<sup>11</sup> compared cutaneous reaction post injection for ILIT and SCIT. SCIT showed three times more incidence of cutaneous reactions compared to ILIT (RR 0.31, 95% CI 0.13 to 0.72; p = 0.007; 1 trial, 114 participants). One trial<sup>11</sup> comparing ILIT and SCIT demonstrated no difference for the incidence of dyspnea following treatment (RR 0.19, 95% CI 0.01 to 3.80; p = 0.270; 1 trial, 114 participants).

Intralymphatic immunotherapy showed increase in specific IgE level following treatment compared to placebo in two trials<sup>24,26</sup> (MD 5.63, 95% CI 0.71 to 10.55; p = 0.020; I² = 0%; 2 trials, 85 participants; low certainty evidence) (Table 3). One trial<sup>10</sup> reported ILIT showed a faster reduction of serum specific IgE level within three months after the completion of treatment as compared to three years for SCIT (MD −4.73, 95% CI −14.73 to 5.27; p = 0.004; 1 trial, 13 participants). Intralymphatic immunotherapy showed reduced reaction of skin prick test by 0.88 mm compared to placebo in two trials<sup>13,24</sup> (MD −0.88, 95% CI −1.53 to −0.23; p = 0.008; 1 trial, 27 participants). Three trials<sup>13,24,25</sup> reported no difference in the quality of life between ILIT and placebo (SMD −0.10, 95% CI −0.86 to 0.67; p = 0.800; I² = 69%; 3 trials, 88 participants; low certainty evidence) (Figure 5, Table 3).
Comparison between ILIT and placebo for local swelling side effect

| Study or Subgroup | ILIT | Placebo | Risk Ratio M-H, Random, 95% CI |
|-------------------|------|---------|-------------------------------|
| Helvikst 2018     | 7    | 30      | 11.0% 15.00 [0.89, 25.142]    |
| Hyander 2013      | 3    | 7       | 12.9% 3.43 [0.45, 25.93]      |
| Hyander 2016      | 11   | 14      | 11.3% 12.27 [0.83, 182.21]    |
| Konradsen 2020    | 13   | 14      | 15.7% 1.11 [0.83, 1.49]       |
| Senti 2012        | 3    | 12      | 13.9% 1.00 [0.21, 4.71]       |
| Skaarup 2020      | 9    | 24      | 11.2% 9.88 [0.62, 156.68]     |
| Thompson 2020     | 3    | 11      | 12.7% 2.73 [0.34, 22.16]      |
| Witten 2013       | 13   | 15      | 11.2% 25.31 [1.65, 389.42]    |

Total (95% CI) 127 101 100% 4.51 [0.81, 25.06]

Comparison between ILIT and placebo for abdominal symptoms side effect

| Study or Subgroup | ILIT | Placebo | Risk Ratio M-H, Random, 95% CI |
|-------------------|------|---------|-------------------------------|
| Helvikst 2018     | 1    | 30      | 28.5% 3.00 [0.13, 70.83]      |
| Hyander 2016      | 1    | 14      | 41.6% 0.50 [0.64, 8.68]       |
| Senti 2012        | 1    | 12      | 29.9% 2.08 [0.09, 45.45]      |

Total (95% CI) 56 45 100% 1.28 [0.24, 6.91]

Comparison between ILIT and placebo for non-specific symptoms (headache, fatigue and muscle soreness)

| Study or Subgroup | ILIT | Placebo | Risk Ratio M-H, Random, 95% CI |
|-------------------|------|---------|-------------------------------|
| Helvikst 2018     | 2    | 30      | 32.1% 1.00 [0.15, 6.64]       |
| Senti 2012        | 0    | 12      | 14.7% 0.14 [0.01, 2.55]       |
| Skaarup 2020      | 3    | 24      | 25.6% 1.50 [0.17, 12.94]      |
| Witten 2013       | 4    | 15      | 27.6% 3.73 [0.47, 29.49]      |

Total (95% CI) 81 64 100% 1.19 [0.37, 3.79]

Comparison between ILIT and placebo for eye and nasal symptoms side effect

| Study or Subgroup | ILIT | Placebo | Risk Ratio M-H, Random, 95% CI |
|-------------------|------|---------|-------------------------------|
| Helvikst 2018     | 5    | 30      | 23.1% 1.67 [0.44, 6.36]       |
| Hyander 2013      | 1    | 7       | 15.4% 0.29 [0.04, 1.99]       |
| Hyander 2016      | 0    | 14      | 8.6% 0.11 [0.01, 1.96]        |
| Senti 2012        | 0    | 12      | 8.6% 0.14 [0.01, 2.55]        |
| Skaarup 2020      | 2    | 24      | 12.8% 2.60 [0.13, 50.25]      |
| Terada 2020       | 5    | 36      | 14.2% 2.50 [0.32, 19.83]      |
| Witten 2013       | 6    | 15      | 21.8% 2.80 [0.67, 11.64]      |

Total (95% CI) 138 97 100% 1.00 [0.38, 2.59]

**FIGURE 4** Secondary outcomes (adverse events) of intralymphatic immunotherapy versus placebo

4 | DISCUSSION

This review found the efficacy and safety of ILIT are not different from placebo in AR management. Most results showed no difference between ILIT and control for the primary and secondary outcomes. Despite most trials reported swelling at the injection site as being the most common adverse event in their patients, the present review found no significant difference in the overall adverse events between ILIT and control.
Comparison between ILIT and placebo for quality of life

| Study or Subgroup | ILIT     | Placebo   | Std. Mean Difference | Std. Mean Difference |
|-------------------|----------|-----------|----------------------|----------------------|
|                   | Mean     | SD        | Total                | Mean     | SD        | Total                | IV, Random, 95% CI | IV, Random, 95% CI |
| Helvikst 2018     | 1.2      | 1.4       | 20                   | 2.2      | 1.4       | 15                   | -0.82 [-1.52, -0.12] | -0.82 [-1.52, -0.12] |
| Konradsen 2020    | 5.96     | 1.59      | 13                   | 5.7      | 2.04      | 12                   | 0.14 [0.05, 0.92]   | 0.14 [0.05, 0.92]   |
| Witten 2013       | 21.79    | 7.37      | 14                   | 18.5     | 7.39      | 14                   | 0.43 [-0.32, 1.18]  | 0.43 [-0.32, 1.18]  |
| Total (95% CI)    | 47       | 100%      |                      | -0.10    | [-0.86, 0.67] |                      |                      |                      |

Heterogeneity: Tau² = 0.32; Chi² = 6.38, df = 2 (P = 0.04); Ι² = 69%
Test for overall effect: Z = 0.25 (P = 0.80)

**FIGURE 5** Secondary outcomes (quality of life) of intralymphatic immunotherapy versus placebo

ILIT and placebo. Whilst most trials did not report severe reaction, a trial by Lee et al.²⁰ reported two patients experienced anaphylaxis following ILIT. Remarkably, the events occurred after the first injection in one patient and second injection in another patient. Both events were attributed to the use of non-standardized allergen extract as compared to standard allergen extract used in other trials. Albeit the limited availability of trials comparing ILIT with other AIT, the results of two trials¹⁰,¹¹ suggest that ILIT has the advantage of less cutaneous reaction and dyspnea to SCIT in addition to the benefit of faster reduction of serum specific IgE level.

We noted the inconsistency of the administration of ILIT in a 2-week interval in one trial¹³ compared with a 4-week interval for others which can be considered as an outlier. The general recommendation for ILIT is three doses given in a 4-week interval for the development of successive waves of antigen-specific immune responses²⁵ but different doses and interval between injection were used among the trials. Although, the impact of this incongruity on the outcome is arguable, standardization of the injection interval is required to ensure comparable outcomes. If further trials are to be conducted to analyze ILIT, using a standardized interval and number of doses to administer ILIT coupled with a suitable outcome measurement such as combined symptoms and medication score would represent a better reflection of the actual potential of ILIT. In trials involving AIT, symptom and medication scores are often assessed independently. The World Allergy Organization taskforce³¹ recommended the standardization of primary endpoint in AIT trial by using the combined symptoms and medication score. As the severity of symptoms entails a higher frequency of medication consumption, this link will be better replicated by combining the symptoms and medication score to indicate their equivalent contribution.

Interestingly, the results of our review contradict the findings of a meta-analysis recently published by Hoang et al.³⁶ which found ILIT confers short term improvement of combined symptoms medication score. The discrepancy can be explained by the different statistical models applied for the meta-analysis, the fixed-effect model in their review and the random-effects model in the present review. We used the random-effects model as it was advocated to account for the heterogeneity across the studies.¹⁶ For the analysis results to be generalized to a population, it should consider the varying resources available to the investigators from study to study which makes it unlikely that the intervention effects across the studies to be identical.

### 4.1 Limitations

High heterogeneity among the trials could be contributed by different allergens exhibiting different immunogenicity effect. One trial²⁴ treated AR patients with polysensitization using grass and birch allergen demonstrated an opposite effect on serological IgE levels. While grass-specific IgE showed a transient increase, birch-specific IgE did not exhibit any alteration. The transient increase of IgE level is attributed to an early phase of desensitization, similarly seen during conventional AIT. Hence, the different immunogenicity effect of different allergen used for ILIT needs to be further investigated.

### 5 CONCLUSIONS

Intralymphatic immunotherapy possibly has a role in the treatment of AR patients. This review found it is safe but not effective, which could be contributed by the high variation amongst the trials. Future trials should involve larger numbers of participants and report standardized administration of ILIT and outcome measures.

### ACKNOWLEDGEMENTS

None.

### CONFLICT OF INTERESTS

Sarah K. Wise is a consultant for NeurENT, Stryker and advisory board member for OptiNose, SinopSys Surgical, ALK-Abello, Genentech. The authors have no other funding, financial relationships, or conflicts of interest to disclose.

### AUTHOR CONTRIBUTIONS

Nur Rahimah Aini, Norhayati Mohd Noor, Mohd Khairi Md Daud, Sarah K. Wise, and Baharudin Abdullah conceptualized and performed the study. Nur Rahimah Aini and Norhayati Mohd Noor made the statistical analysis. Nor Rahimah Aini, Norhayati Mohd Noor, Mohd Khairi Md Daud, Sarah K. Wise, and Baharudin Abdullah wrote the manuscript. All authors approved the final version of the manuscript before submission.

### ORCID

Baharudin Abdullah <https://orcid.org/0000-0001-9138-9215>
REFERENCES

1. Bouquet J, Khaltaev N, Cruz AA, et al. Allergic rhinitis and its impact on asthma (ARIA) 2008. Allergy. 2008;63:8-160.

2. Asher MI, Montefort S, Bjorksten B, et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. Lancet. 2006;368(9537):733-743.

3. Bouquet J, Lockey R, Malling HJ. Allergen immunotherapy: therapeutic vaccines for allergic diseases A WHO position paper. J Allergy Clin Immunol. 1998;102(4 Pt 1):558-562.

4. Price D, Bond C, Bouchard J, et al. International primary care respiratory group (IPCRG) guidelines: management of allergic rhinitis. Prim Care Respir J. 2006;15(1):58-70.

5. Scadding G, Durham S, Mirakian R, et al. BSACI guidelines for the management of allergic and non-allergic rhinitis. Clin Exp Allergy. 2008;38(1):19-42.

6. Calderon MA, Alves B, Jacobson M, Hurwitz B, Sheikh A, Durham S. Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev. 2007;2007(1):CD001936.

7. Cox L, Nelson H, Lockey R, et al. Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol. 2011;127(Suppl 1):S1-555.

8. Canonica GW, Bouquet J, Casale T, et al. Sub-lingual immunotherapy: World allergy organization position paper 2009. World Allergy Organ J. 2009;2:233-281.

9. Johansen P, Haffner A, Koch F, et al. Direct intralymphatic injection of peptide vaccines enhances immunogenicity. Eur J Immunol. 2005;35(2):568-574.

10. Hylander T, Latif L, Petersson-Westin U, Cardell LO. Intralymphatic allergen-specific immunotherapy: an effective and safe alternative treatment route for pollen-induced allergic rhinitis. J Allergy Clin Immunol. 2013;131(2):412-420.

11. Senti G, Prinz Vavrivcik BM, Erdmann I, et al. Intralymphatic allergen administration renders specific immunotherapy faster and safer: a randomized controlled trial. Proc Natl Acad Sci U S A. 2008;105(46):17908-17912.

12. Senti G, Crameri R, Kuster D, et al. Intralymphatic immunotherapy for cat allergy induces tolerance after only 3 injections. J Allergy Clin Immunol. 2012;129(5):1290-1296.

13. Witten M, Malling HJ, Blom L, Poulsen BC, Poulsen LK. Is intralymphatic immunotherapy ready for clinical use in patients with grass pollen allergy? J Allergy Clin Immunol. 2013;132(5):1248-1252.e5.

14. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151:264-269, w64.

15. GRADEpro G. Computer Program on wwwGRADEpro.org. Version [July, 2016]. McMaster University: 2014.

16. Higgins JP, Green S, eds. Cochrane handbook for systematic reviews of interventions. Wiley: 2011.

17. Collaboration C. Review Manager (RevMan) Version 5.3. Copenhagen: The Nordic Cochrane Centre; 2014.

18. Patterson AM, Bonny AE, Shiels WE, 2nd, Erwin EA. Three-injection intralymphatic immunotherapy in adolescents and young adults with grass pollen rhinoconjunctivitis. Ann Allergy Asthma Immunol. 2016;116(2):168-170.

19. Schmid JM, Nezam H, Madsen HH, Schmitz A, Hoffmann HJ. Intralymphatic immunotherapy induces allergen specific plasmablasts and increases tolerance to skin prick testing in a pilot study. Clin Transl Allergy. 2016;6:19.

20. Lee SP, Choi SJ, Joe E, et al. A pilot study of intralymphatic immunotherapy for house dust mite, cat, and dog allergies. Allergy Asthma Immunol Res. 2017;9(3):272-277.

21. Ahlbeck L, Ahlberg E, Nyström U, Bjorkander J, Jenmalm MC. Intralymphatic allergen immunotherapy against pollen allergy: a 3-year open follow-up study of 10 patients. Ann Allergy Asthma Immunol. 2018;121(5):626-627.

22. Weinfeld D, Westin U, Hellkvist L, Mellqvist UH, Jacobsson I, Cardell LO. A preseason booster prolongs the increase of allergen specific IgG4 levels, after basic allergen intralymphatic immunotherapy, against grass pollen seasonal allergy. Allergy Asthma Clin Immunol. 2020;16:31.

23. Hylander T, Larsson O, Petersson-Westin U, et al. Intralymphatic immunotherapy of pollen-induced rhinoconjunctivitis: a double-blind placebo-controlled trial. Respir Res. 2016;17:10.

24. Hellkvist L, Hjalmarsson E, Kumlien Georen S, et al. Intralymphatic immunotherapy with 2 concomitant allergens, birch and grass: a randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol. 2018;142(4):1338-1341.e9.

25. Konradsen JR, Grundstrom J, Hellkvist L, et al. Intralymphatic immunotherapy in pollen-allergic young adults with rhinoconjunctivitis and mild asthma: a randomized trial. J Allergy Clin Immunol. 2020;145(3):1005-1007.

26. Skaarup SH, Schmid JM, Skjold T, Graumann O, Hoffmann HJ. Intralymphatic immunotherapy improves grass pollen allergic rhinoconjunctivitis: a 3-year randomized placebo-controlled trial. J Allergy Clin Immunol. 2020;S0091-6749(20):30964-30967.

27. Thompson CP, Silvers S, Shapiro MA. Intralymphatic immunotherapy for mountain cedar pollinosis: a randomized, double-blind, placebo-controlled trial. Ann Allergy Asthma Immunol. 2020;125(3):311-318.

28. Terada T, Oumura S, Kikuoka Y, et al. Sustained effects of intralymphatic pollen-specific immunotherapy on Japanese cedar pollinosis. Rhinology. 2020;58(3):241-247.

29. Juniper EF, Guyatt GH. Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis. Clin Exp Allergy. 1991;21(1):77-83.

30. Juniper EF, Guyatt GH, Epstein RS, Ferrie PJ, Jaeschke R, Hiller TK. Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials. Thorax. 1992;47(2):76-83.

31. Canonica GW, Baena-Cagnani CE, Bouquet J, et al. Recommendations for standardization of clinical trials with Allergen Specific Immunotherapy for respiratory allergy. A statement of a World Allergy Organization (WAO) taskforce. Allergy. 2007;62(3):317-324.

32. Hoang MP, Seresirikachorn K, Chitsthupakorn W, Snidvongs K. Intralymphatic immunotherapy for allergic rhinoconjunctivitis: a systematic review and meta-analysis. Rhinology. 2021;59(3). https://doi.org/10.4193/Rhin20.572

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section at the end of this article.

How to cite this article: Aini NR, Mohd Noor N, Md Daud MK, Wise SK, Abdullah B. Efficacy and safety of intralymphatic immunotherapy in allergic rhinitis: a systematic review and meta-analysis. Clin Transl Allergy. 2021:e12055. https://doi.org/10.1002/cti.12055